ストックスクリーナーアプリを入手
0.394
0.93%
-0.0037
アフターアワーズ：
.39
-0.004
-1.02%
前日終値:
$0.3977
開ける：
$0.3955
24時間の取引高:
2.36M
Relative Volume:
0.17
時価総額：
$62.70M
収益：
$10.00M
当期純損益:
$-29.47M
株価収益率:
-1.97
EPS:
-0.2
ネットキャッシュフロー:
$-21.55M
1週間 パフォーマンス:
-6.41%
1か月 パフォーマンス:
-25.25%
6か月 パフォーマンス:
-77.36%
1年 パフォーマンス:
-84.37%
1日の値動き範囲:
$0.381
$0.4199
1週間の範囲:
$0.381
$0.4543
52週間の値動き範囲:
$0.20
$3.05
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
名前
Mereo Biopharma Group Plc Adr
セクター
電話
4403330237300
住所
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.394 | 63.29M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-30 | ダウングレード | Jefferies | Buy → Hold |
| 2025-03-27 | 開始されました | JP Morgan | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-13 | 再開されました | BTIG Research | Buy |
| 2022-08-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Needham | Buy |
すべてを表示
Mereo Biopharma Group Plc Adr (MREO) 最新ニュース
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Mereo BioPharma Group plcSponsored ADR $MREO Stock Holdings Raised by Aberdeen Group plc - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - ChartMill
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - marketscreener.com
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - Finviz
Mereo BioPharma Faces Securities Litigation - Intellectia AI
MREO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Mereo BioPharma Group plc Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsMREO - ChartMill
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc - Barchart.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Chartmill
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit - Chartmill
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Hold” by Brokerages - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - ChartMill
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo Biopharma Group Plc Adr (MREO) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):